Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial

Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial

Abstract Background The prognosis of patients with previously treated advanced gastric or gastroesophageal junction (GEJ) cancer remains poor. Given the robust development of immunotherapy and targeted therapy during the last decades, we aimed to investigate if the combination of traditional second-...

Full description

Bibliographic Details
Main Authors: Le Zhang, Weixue Wang, Shaohua Ge, Hongli Li, Ming Bai, Jingjing Duan, Yuchong Yang, Tao Ning, Rui Liu, Xia Wang, Zhi Ji, Feixue Wang, Haiyang Zhang, Yi Ba, Ting Deng
Format: Article
Language:English
Published: BMC 2023-03-01
Series:BMC Cancer
Subjects:
Immune checkpoint inhibitors
Molecular targeted therapy
Sintilimab
Apatinib
Gastric cancer
Online Access:https://doi.org/10.1186/s12885-023-10661-4

Internet

https://doi.org/10.1186/s12885-023-10661-4

Similar Items